{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:02:01Z","timestamp":1777006921248,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Background<\/jats:title>\n Hypertension and Type 2 Diabetes Mellitus (T2DM) interact to increase cardiorenal risk. This study evaluated the cardiorenal efficacy of dapagliflozin combined with valsartan in patients with coexisting T2DM and hypertension.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective cohort study included 245 patients admitted between January 2023 and December 2024. Propensity score matching yielded 102 patients in the Monotherapy Group (valsartan 80 mg\/day) and 102 in the Combination Group (valsartan 80 mg\/day + dapagliflozin 10 mg\/day). Outcomes assessed at baseline and 24 weeks included blood pressure, glycemic parameters (FPG, 2hPG, GluCV, PGE, LAGE, MAGE), inflammatory and cardiac biomarkers (hs-CRP, TNF-\u03b1, IL-6, IL-33, sST2, sICAM-1), echocardiographic measures (LVEF, LVEDD, LVESD, LAD, IVSd), NT-proBNP, renal function (eGFR, UACR, SCr, BUN), and fibrosis markers (PIIINP, C-IV, LN, TGF-\u03b21).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At 24 weeks, the Combination Group showed greater reductions in systolic (134.86 \u00b1 6.37 vs. 139.68 \u00b1 6.82 mmHg) and diastolic blood pressure (83.12 \u00b1 4.58 vs. 86.29 \u00b1 4.79 mmHg), FPG (6.79 \u00b1 1.02 vs. 7.58 \u00b1 1.10 mmol\/L), 2hPG (9.71 \u00b1 1.68 vs. 11.24 \u00b1 1.84 mmol\/L), and glycemic variability indices (all P &lt; 0.001). Inflammatory and cardiac biomarkers declined more markedly (P &lt; 0.05). Significant improvements were also observed in LVEF (60.12 \u00b1 4.68% vs. 56.75 \u00b1 4.96%), NT-proBNP, eGFR, UACR, and fibrosis markers (all P &lt; 0.05). Multivariate analysis showed combination therapy independently predicted better outcomes (OR\u00a0=\u00a02.417, 95% CI: 1.315\u20134.443, P\u00a0=\u00a00.004).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The addition of dapagliflozin to valsartan was associated with superior cardiorenal outcomes compared to valsartan monotherapy in patients with T2DM and hypertension, as evidenced by enhanced improvements in blood pressure, glycemic control, inflammation, cardiac function, and renal parameters.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2026.1804226","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:29:55Z","timestamp":1777004995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal protective effects of dapagliflozin combined with valsartan in patients with type 2 diabetes mellitus and hypertension: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhengrong","family":"Zhou","sequence":"first","affiliation":[{"name":"Medical Department, Yangzhou University","place":["Yangzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaizheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Yangzhou University","place":["Yangzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2024.2426442","article-title":"Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study","volume":"136","author":"Geng","year":"2024","journal-title":"Postgrad Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00005176-200505000-00217","article-title":"Prevalences of hypertension, type 2 diabetes mellitus, and cardiovascular disease in a cohort of Puerto Ricans with non-alcoholic fatty liver disease","volume":"43","author":"Gonz\u00e1lez-Rivera","year":"2024","journal-title":"P R Health Sci J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12933-024-02391-z","article-title":"Detecting heart stress using NT-proBNP in patients with type 2 diabetes mellitus and hypertension or high-normal blood pressure: a cross-sectional multicentric study","volume":"23","author":"Landolfo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12902-024-01750-x","article-title":"Association between visceral adiposity index, lipid accumulation product and type 2 diabetes mellitus in US adults with hypertension: a cross-sectional analysis of NHANES from 2005 to 2018","volume":"24","author":"Lv","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.59556\/japi.72.0620","article-title":"Management of hypertension in patients with type 2 diabetes mellitus: Indian guideline 2024 by Association of Physicians of India and Indian College of Physicians","volume":"72","author":"Wander","year":"2024","journal-title":"J Assoc Physicians India"},{"key":"B7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.18332\/popmed\/164769","article-title":"Geospatial analysis of type 2 diabetes mellitus and hypertension in South Sulawesi, Indonesia","volume":"13","author":"Zainuddin","year":"2023","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihad047","article-title":"Prevalence of hypertension among type 2 diabetes mellitus patients in China: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2024","journal-title":"Int Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1212878","article-title":"Association of sleep behaviors, insulin resistance surrogates, and the risk of hypertension in Chinese adults with type 2 diabetes mellitus","volume":"14","author":"Yao","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.110.p123","article-title":"Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus","volume":"174","author":"Pankova","year":"2024","journal-title":"Wien Med Wochenschr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1186\/s12889-024-18290-7","article-title":"The interaction between general or abdominal obesity and hypertension on the risk of type 2 diabetes mellitus: a cross-sectional analysis in Iranian adults from the RaNCD cohort study","volume":"24","author":"Pasdar","year":"2024","journal-title":"BMC Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2269854","article-title":"Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Dholariya","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1369-22","article-title":"Marked increase in urinary C-peptide levels after treatment with sacubitril\/valsartan in patients with type 2 diabetes mellitus and hypertension","volume":"62","author":"Tanji","year":"2023","journal-title":"Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1528801","article-title":"Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus - a phase 4 study in India","volume":"16","author":"Wangnoo","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.12.2023.093","article-title":"Impact of dapagliflozin adjunctive therapy on the progression of chronic kidney disease in patients with type 2 diabetes and chronic kidney disease stages 2-5: a systematic review and meta-analysis","volume":"24","author":"Kanimozhi","year":"2024","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110755","article-title":"Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension","volume":"123","author":"Wei","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-015-0931-3","article-title":"Diabetes mellitus: definition, classification and diagnosis","author":"Roden","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"B18","article-title":"Hypertensive crisis","volume":"73","author":"Xhignesse","year":"2018","journal-title":"Rev Med Liege"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2407187","article-title":"Two-drug combinations therapy of different doses of valsartan existing diverse significance for hypertensive patients","volume":"24","author":"Wang","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1321095","article-title":"Valsartan attenuates LPS-induced ALI by modulating NF-\u03baB and MAPK pathways","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.303","article-title":"Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Seidu","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-022-01445-4","article-title":"HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target","volume":"21","author":"Ceriello","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s418520","article-title":"Correlation between glycemic variability and diabetic complications: a narrative review","volume":"16","author":"Huang","year":"2023","journal-title":"Int J Gen Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/ijnrd.s234282","article-title":"Clinical evaluation of dapagliflozin in the management of CKD: focus on patient selection and clinical perspectives","volume":"15","author":"Nashar","year":"2022","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.3390\/jcm10184078","article-title":"Glycemic variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.103522","article-title":"Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats","volume":"30","author":"Alanazi","year":"2023","journal-title":"Saudi J Biol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.060805","article-title":"SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","article-title":"The potential anti-arrhythmic effect of SGLT2 inhibitors","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1357673","DOI":"10.1016\/s0735-1097(24)02618-4","article-title":"Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction","volume":"15","author":"Arbel","year":"2024","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00680-5","article-title":"Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes","volume":"10","author":"Nagahisa","year":"2019","journal-title":"Diabetes Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.3390\/ijms25137057","article-title":"The renoprotective mechanisms of sodium-glucose cotransporter-2 inhibitors (SGLT2i)-a narrative review","volume":"25","author":"Iordan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1804226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:29:56Z","timestamp":1777004996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1804226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":37,"alternative-id":["10.3389\/fendo.2026.1804226"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1804226","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1804226"}}